This technology allows an injected cancer drug to remain inactive until it is transported to a tumor. Once inside the tumor, remote radiation is applied, which activates the drug and 100% of the energy is released within the tumor. This is a novel concept of completely bypassing oxygen quenching by linking a prodrug to a nanocrystal radiation scintillator. For decades’ medical radiation specialists have sought to activate by local radiation beams, a non-toxic, interactive version of a cancer drug, (E. G., A pro-drug) selectively at cancers and not body tissues in general. This strategy is attractive because it aims to overwhelm tumor resistant mechanisms by allowing high drug concentrations at tumor foci while sparing normal tissue and organs from toxicity, and reducing the generally damaging radiation doses needed to control tumor burden. Drug activity focused on areas adjacent to tumors that would destroy the micrometastasis that is so challenging to selectively excise or treat would be desirable. Single cell infiltration that significantly diminishes by a blading the active margin of primary and secondary tumors, especially in early disease stages, would also be desirable. Global Cancer Technology has acquired the primary patent for this process and will develop additional patents.